Results Forecasts
Consolidated Earnings Forecasts
The following shows our consolidated earnings forecasts for fiscal year ending March 31, 2027. (Updated in May 2026)
(billions of yen)
| Results for the Fiscal Year Ended March 31, 2026 | fiscal year ending March 31, 2027 forecasts | Change | % change | |
|---|---|---|---|---|
| Net Sales | 500.0 | 53.5 | 3.5 | 7.0% |
| Operating Profit | 51.8 | 58.0 | 6.1 | 11.9% |
| Profit attributable to owners of the parent | 35.4 | 36.0 | 0.5 | 1.5% |
| Diluted earnings per share（yen） | 56.89 | 57.93 | 1.04 | 1.8% |
Sales Forecast By Destination
(billions of yen)
| Results for the Fiscal Year Ended March 31, 2026 | fiscal year ending March 31, 2027 forecasts | Change | % change | |
|---|---|---|---|---|
| Japan | 58.6 | 72.0 | 13.3 | 22.9% |
| Americas | 139.2 | 152.0 | 12.7 | 9.2％ |
| EMEA | 158.0 | 174.0 | 15.9 | 10.1% |
| China | 89.4 | 75.0 | -14.4 | -16.2% |
| Asia-Pacific | 54.6 | 62.0 | 7.3 | 13.5% |
| Total | 500.0 | 535.0 | 35.0 | 7.0% |
- ※EMEA: Europe, Middle East, and Africa
Sales Forecast By Business
(billions of yen)
| Results for the Fiscal Year Ended March 31, 2026 | fiscal year ending March 31, 2027 forecasts | Change | % change | ||
|---|---|---|---|---|---|
| Diagnostics Business | Hematology | 299.4 | 317.0 | 17.5 | 5.9% |
| FCM | 4.6 | 7.0 | 2.3 | 49.2% | |
| Urinalysis | 44.0 | 48.5 | 4.4 | 10.1% | |
| Hemostasis | 72.4 | 74.0 | 1.5 | 2.2% | |
| Immunochemistry | 22.3 | 23.0 | 0.6 | 3.0% | |
| Clinical Chemistry | 2.9 | 13.0 | 10.0 | 345.5% | |
| Life Science | 24.9 | 23.5 | -1.4 | -5.9% | |
| Others | 25.9 | 23.5 | -2.4 | -9.4% | |
| Medical Robotics Business | 3.3 | 5.5 | 2.1 | 66.4% | |
| Total | 500.0 | 535.0 | 35.0 | 7.0% | |